Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2014; 20(17): 5119-5123
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5119
Efficacy of ilaprazole in the treatment of duodenal ulcers: A meta-analysis
Xi-Qing Ji, Jun-Feng Du, Gang Chen, Guang Chen, Bo Yu
Xi-Qing Ji, Jun-Feng Du, Gang Chen, Guang Chen, Bo Yu, Department of General Surgery, General Hospital of Beijing Military Command of People’s Liberation Army, Beijing 100700, China
Author contributions: Ji XQ and Yu B designed research; Ji XQ, Du JF and Chen G performed research; Ji XQ, Chen G and Yu B wrote the paper.
Supported by The National Natural Science Foundation of China, No. 81000189
Correspondence to: Bo Yu, MD, Department of General Surgery, General Hospital of Beijing Military Command of People’s Liberation Army, No. 5, Nanmencang, Dongsi, Beijing 100700, China. yubobeizong@126.com
Telephone: +86-10-84008099 Fax: +86-10-66721188
Received: October 21, 2013
Revised: January 22, 2014
Accepted: March 8, 2014
Published online: May 7, 2014
Abstract

AIM: To compare the efficacy and tolerance of ilaprazole compared with other proton pump inhibitors (PPIs) in the treatment of duodenal ulcer.

METHODS: An electronic database search of Medline, Embase, the Cochrane controlled trials register, Web of Science, PubMed, and the Chinese Biomedical Literature Database (updated to July 2013), and manual searches were conducted. A meta-analysis of randomized controlled trials comparing the efficacy and tolerance of ilaprazole and other PPIs in the treatment of duodenal ulcers was performed.

RESULTS: Five articles involving 1481 patients were included. The meta-analysis showed no difference in the 4-wk healing rate between ilaprazole and other PPIs [89.7% vs 87.0%; relative risk (RR) = 1.02; 95%CI: 0.98-1.06; Z = 1.00; P = 0.32]. The results did not change in the sensitivity analyses. The meta-analysis indicated that the adverse effect rate in the ilaprazole group was lower than that in the control group, but the difference was not significant (9.7% vs 13.0%; RR = 0.81; 95%CI: 0.60-1.07; Z = 1.47; P = 0.14).

CONCLUSION: Ilaprazole is a highly effective and safe PPI in the treatment of duodenal ulcers. Ilaprazole can be recommended as a therapy for acid-related disorders, especially in Asian populations.

Keywords: Ilaprazole, Proton pump inhibitor, Duodenal ulcer, Meta-analysis

Core tip: Ilaprazole, a proton pump inhibitor (PPI), is a newly developed medicine in the management of acid-related disorders. This meta-analysis showed that ilaprazole was a highly effective and safe PPI compared with other PPIs in the treatment of duodenal ulcer. Ilaprazole can be recommended as a therapy for acid-related disorders, especially in Asian populations.